Skip to main content
SpringerLink
Log in

Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: A multi-modality approach combining surgery with aggressive chemotherapy and radiation is used to treat advanced neuroblastoma. Despite this treatment, children with advanced disease have a 20% 2-year survival rate. Controversy has developed regarding the efficacy of combining aggressive chemotherapy with repeated surgical intervention aimed at providing a complete surgical resection (CSR) of the primary tumor and metastatic sites. Several prospective and retrospective studies have provided conflicting reports regarding the benefit of this approach on overall survival. Therefore, we evaluated the efficacy of CSR versus partial surgical resection (PSR) using a strategy combining surgery with aggressive chemotherapy, radiation, and bone marrow transplantation (BMT) for stage IV neuroblastoma.

Methods: A retrospective study was performed with review of the medical records of 52 consecutive children with neuroblastoma treated between 1985 and 1993. Twenty-eight of these 52 children presented with advanced disease, 24 of which had sufficient data to allow for analysis. All children were managed with protocols designed by the Children's Cancer Group (CCG). Statistical analysis was performed using Student'st test,x 2 test, and Kaplan-Meier survival curves.

Results: Mean survival (35.1 months) and progression-free survival (29.1 months) for the CSR children was statistically superior to that of the PSR children (20.36 and 16.5 months, p=0.04 and 0.04, respectively). Similar significance was demonstrated using life table analysis of mean and progression-free survival of these two groups (p=0.05 and <0.01, respectively). One-, 2-, and 3-year survival rates for the CSR versus the PSR group were 100%, 80%, and 40% versus 77%, 38%, and 15%, respectively. An analysis of the BMT group compared with those children treated with aggressive conventional therapy showed improvement in mean and progression-free survival.

Conclusions: Aggressive surgical resection aimed at removing all gross disease is warranted for stage IV neuroblastoma. CSR is associated with prolonged mean and progression-free survival. BMT prolongs mean and progression-free survival in children with stage IV disease. These results suggest that CSR and BMT offer increased potential for long-term remission in children with advanced neuroblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grosfeld JL. Neuroblastoma: a 1990 overview.Pediatr Surg Int 1991;6:9–13.

    Google Scholar 

  2. Losty P, Quinn F, Breatnach F, O'Meara A, Fitzgerald RJ. Neuroblastoma—a surgical perspective.Eur J Surg Oncol 1993;19:33–6.

    CAS  PubMed  Google Scholar 

  3. Malone PS, Marwaha RK, Kiely EM, Spitz L, Walker D, Pritchard J. The role of radical surgery in the management of advanced abdominal neuroblastoma [Meeting Abstract].Med Pediatr Oncol 1990;18:377.

    Google Scholar 

  4. Krivit W, Siegel S, Seeger R, Wong KY, Sather H, Hammond D. Randomized prospective multi-agent therapy in advanced neuroblastoma (NBL).Proc Am Soc Clin Oncol 1987;6:A872, 221.

    Google Scholar 

  5. Bowman LC, Hancock ML, Santana VM, et al. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: the St. Jude's Children's Research Hospital experience, 1962–1988.J Clin Oncol 1991;9:1599–608.

    CAS  PubMed  Google Scholar 

  6. O'Neill JA, Littman P, Blitzer P, Soper K, Chatten J, Shimada H. The role of surgery in localized neuroblastoma.J Pediatr Surg 1985;20:708–12.

    PubMed  Google Scholar 

  7. Sitarz A, Finkelstein J, Grosfeld J, et al. An evaluation of the role of surgery in disseminated neuroblastoma: a report from the Children's Cancer Study Group.J Pediatr Surg 1983;18:147–51.

    CAS  PubMed  Google Scholar 

  8. Shimada H, Chatten J, Newton WA, Sachs N, Hamoudi AB, Chiba T, Marsden HB. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age linked classification of neuroblastomas.J Natl Cancer Inst 1984;73:405–16.

    CAS  PubMed  Google Scholar 

  9. Kaplan EL, Meier P. Non parametric estimation from incomplete observations.J Am Stat Assoc 1958;53:457–81.

    Google Scholar 

  10. Mantel N. Evaluation of survival data and two new rank order statistics arising in consideration.Cancer Chemother Rep 1966;50:163–70.

    CAS  PubMed  Google Scholar 

  11. Adams GA, Shochat SJ, Smith EI, et al. Thoracic neuroblastoma: a Pediatric Oncology Group study.J Pediatr Surg 1993;28:372–7.

    Article  CAS  PubMed  Google Scholar 

  12. Coldman AJ, Fryer CJH, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site and sex on prognosis.Cancer 1980;46:1896–900.

    CAS  PubMed  Google Scholar 

  13. Kretschmar CS, Frantz CN, Rose EM, Cassady JR, Levey R, Sallen SE. Improved prognosis for infants with stage IV neuroblastoma.J Clin Oncol 1984;2:799–803.

    CAS  PubMed  Google Scholar 

  14. Nitschke R, Smith EI, Shochat S, et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study.J Clin Oncol 1988;9:1271–9.

    Google Scholar 

  15. Ninane J, Wese FX. Treatment of localized neuroblastoma.Am J Pediatr Hematol Oncol 1988;8:248–52.

    Google Scholar 

  16. Haase GM, Wong KY, de Lorimier AA, Sather HN, Hammond GD. Improvement in survival after excision of primary tumor in stage III neuroblastoma.J Pediatr Surg 1989;24:194–200.

    CAS  PubMed  Google Scholar 

  17. LeTourneau JN, Bernard JL, Hendren WH, Carcassonne M. Evaluation of the role of surgery in 130 patients with neuroblastoma.J Pediatr Surg 1985;20:244–9.

    CAS  Google Scholar 

  18. Haase GM, O'Leary MO, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma.J Pediatr Surg 1992;27:616–22.

    Google Scholar 

  19. Shorter NA, Davidoff AM, Evans AE, Ross AJ, Ziegler MM, O'Neill Ja. The role of surgery in the management of stage IV neuroblastoma [Meeting Abstract].Med Pediatr Oncol 1990;18:377.

    Google Scholar 

  20. Matsumura M, Atkinson JB, Hays DM, et al. An evaluation of the role of surgery in metastatic neuroblastoma.J Pediatr Surg 1988;23:448–53.

    CAS  PubMed  Google Scholar 

  21. Shamberger RC, Allarde-Segundo A, Kozakewich HP, Grier HE. Surgical management of stage III and IV neuroblastoma: resection before or after chemotherapy.J Pediatr Surg 1991;26:1113–8.

    CAS  PubMed  Google Scholar 

  22. Ikeda K, Nakagawara A, Yano H, et al. Improved survival rates in children over 1 year of age with stage III or IV neuroblastoma following an intensive chemotherapeutic regimen.J Pediatr Surg 1989;24:189–93.

    CAS  PubMed  Google Scholar 

  23. Pritchard J, McElwain TJ, Graham-Pole J. High dose mephalan with autologous bone marrow treatment of advanced neuroblastoma.Br J Cancer 1982;45:86–94.

    CAS  PubMed  Google Scholar 

  24. August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation and allogenic or autologous marrow reconstitution.J Clin Oncol 1984;2:609–16.

    CAS  PubMed  Google Scholar 

  25. Seeger RC, Matthay KK, Villablanca JG, et al. Intensive chemotherapy and autologous bone marrow transplantation (ABMT) for high risk neuroblastoma.Proc Annu Meet Am Soc Clin Oncol 1991;10:A1089.

    Google Scholar 

  26. Rajantie J, Wikstrom S, Perkkio M, et al. Improved prognosis for children with stage IV neuroblastoma: high dose mephalan and autologous unpurged marrow transplantation after aggressive surgery and short chemotherapy with cisplantinum and etoposide.Pediatr Hematol Oncol 1988;5:125–35.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Department of Surgery, George Washington University Medical Center, Washington, DC, USA

    Ronald S. Chamberlain MD

  2. Departments of Pediatrics, and Hematology and Oncology, Children's National Medical Center, Washington, DC, USA

    Ralph Quinones MD, Patricia Dinndorf MD, Nasser Movassaghi MD &  Kurt Newman MD

  3. George Washington University School of Medicine, Washington, DC, USA

    Miriam Goodstein

Authors
  1. Ronald S. Chamberlain MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph Quinones MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia Dinndorf MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nasser Movassaghi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Miriam Goodstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kurt Newman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chamberlain, R.S., Quinones, R., Dinndorf, P. et al. Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma. Annals of Surgical Oncology 2, 93–100 (1995). https://doi.org/10.1007/BF02303622

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02303622

Key Words

Search

Navigation